# TRI-611

Source: https://onco.cc/drugs/tri-611/  
OnCo record `tri-611` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TRI-611 is an experimental protein degrader from TRIANA Biomedicines in phase 2 trials for non-small-cell lung cancer, aimed at ALK.

## Summary

TRI-611 is a protein degrader developed by TRIANA Biomedicines. Its target is ALK (the sponsor names ALK). The sponsor states: TRI-611 is an oral, brain-penetrant molecular glue degrader that brings ALK fusion proteins and cereblon together through a mechanism independent of the kinase active site, driving degradation of ALK fusion proteins in ALK-positive NSCLC. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07491497, plans to enrol 160 participants with primary completion expected 2029-05-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: protein degrader
- Mechanism: TRI-611 is an oral, brain-penetrant molecular glue degrader that brings ALK fusion proteins and cereblon together through a mechanism independent of the kinase active site, driving degradation of ALK fusion proteins in ALK-positive NSCLC.

## Sources

- ClinicalTrials.gov: trials of TRI-611: https://clinicaltrials.gov/search?intr=TRI-611
- Sponsor pipeline page: https://www.trianabio.com/pipeline

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [ALK](https://onco.cc/targets/alk/)
- companies: [Triana Biomedicines](https://onco.cc/companies/triana-biomedicines/)
- trials: [A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC](https://onco.cc/trials/nct07491497/)

---
JSON: https://onco.cc/api/v1/entities/tri-611.json